Multiple Etiology Dementias: Facilitate basic and clinical research (Milestone 2.L)
In Progress
Timeline Start - End
2016 - 2027Research Implementation Area
Research on Disease MechanismsAD-Related Dementias Focus
Advance basic research on the common and interacting risk factors and mechanisms of multiple etiology cognitive impairment and dementia in diverse populations.
Success Criteria
- At least three new mechanistic projects on interacting molecular pathways and risk factors that either accelerate or protect against cognitive decline and dementia in general and diverse US populations.
Summary of Key Accomplishments
In FY18 and FY19, NIH released funding opportunities on common mechanisms of AD/ADRD (PAS-17-028) and to identify new potential clinical targets (PAR-18-661) that can detect characteristics of AD vs. ADRDs as compared to healthy individuals. One award is describing, at a cellular level, molecular signatures of AD, LBD, FTD and healthy individuals, and researchers have published promising, initial results. NINDS also funds the “Center Without Walls for Imaging Proteinopathies with PET,” which is developing novel, sophisticated technology to visualize and differentiate several different AD- and ADRD-related brain changes. The Dementia Nomenclature Initiative continues to work on developing consistent, accurate, and meaningful language for cognitive impairment and dementia, including how best to describe and communicate the difference between multiple etiology dementia and other versions of AD/ADRDs.
The key accomplishments summary is current as of July 2022.
Accomplishments/Implementation Activities
Funding Initiatives
- PAS-17-028: Common Mechanisms and Interactions Among Neurodegenerative Diseases (R01)
- PAR-18-661: Pathway and Target Identification for Alzheimer's Disease Related Dementias (ADRDs)
- RFA-NS-19-026: Clinical and Biological Measures of TBI-related dementia including Chronic Traumatic Encephalopathy (CTE) (R01)
- RFA-NS-19-030: Neuropathological Assessment of TBI-related Neurodegeneration and Neurocognitive Decline - Center Without Walls (NATBI CWOW) (U54)
- PAR-19-167: Development and Validation of Advanced Mammalian Models for Alzheimer's Disease-Related Dementias (ADRD) (R61/R33)
- RFA-NS-19-027: Human Three-Dimensional Cell Model Systems for Alzheimer's Disease-Related Dementias (ADRDs) (UG3/UH3)
- RFA-NS-20-005: Mechanistic Basis of TDP-43-Dependent Pathobiology in Common Dementias (R01)
- RFA-NS-21-006: Mechanisms of Pathological Spread of Abnormal Proteins in LBD and FTD (R01 Clinical Trial Not Allowed)
- NOT-NS-21-040: Administrative Supplements for Collaborative Activities to Promote Sleep/Circadian Research in ADRD
- PAR-22-023: Multi-Disciplinary Collaborations to Understand Mechanisms of Systemic Immune Signaling and Inflammation in ADRD and its Progression (R01 Clinical Trial Not Allowed)
- PAR-22-029: Longitudinal Single Cell Characterization of ADRD Postmortem Tissue (R01 Clinical Trial Not Allowed)
- PAR-22-037: Role of Astrocytes in Degeneration of the Neurovascular Unit in AD/ADRDs (R01 Clinical Trial Not Allowed)
- PAR-22-048: Clinical Relevance of the Linkage between Environmental Toxicant Exposures and Alzheimer’s Disease and Related Dementias (R01 Clinical Trial Not Allowed)
- https://grants.nih.gov/grants/guide/pa-files/par-22-059.html
- PAR-22-211: Impact of the Microbiome-Gut-Brain Axis on Alzheimer's Disease and Alzheimer's Disease-Related Dementias (R01 Clinical Trial Not Allowed)
- PAR-22-235: Blood Brain Barrier Response to Antibodies Targeting Beta-Amyloid (R01 - Clinical Trial Not Allowed)
Research Programs and Resources
- Pathway and Target Identification for Alzheimer's Disease Related Dementias (ADRDs)
- Clinical and Biological Measures of TBI-related dementia including Chronic Traumatic Encephalopathy (CTE) (R01)
- Neuropathological Assessment of TBI-related Neurodegeneration and Neurocognitive Decline - Center Without Walls (NATBI CWOW) (U54)
- Development and Validation of Advanced Mammalian Models for Alzheimer's Disease-Related Dementias (ADRD) (R61/R33)
- Human Three-Dimensional Cell Model Systems for Alzheimer's Disease-Related Dementias (ADRDs) (UG3/UH3)
- Center Without Walls for Imaging Proteinopathies with PET (CW2IP2)
- Select projects funded in FY21
- Select projects funded in FY22
- Alzheimer’s Disease Research Centers
- Mind Your Risks
Research Highlights
Relevant Recommendations
- 2016 ADRD Summit: Multiple Etiology Dementias (MED) Focus Area 2: Basic and Clinical Research in Interactions between Dementia Pathophysiologies, Recommendation 5(PDF, 694K)
- 2022 ADRD Summit: Multiple Etiology Dementias (MED) Milestone 4, Priority 2